Results 11 to 20 of about 74,496 (193)
Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2010 Review on JAK2 (janus kinase 2), with data on DNA, on the protein encoded, and where the gene is implicated.
Huret, JL
openaire +4 more sources
Janus kinase inhibitors: jackpot or potluck? [PDF]
Oncology Reviews, 2012 The reports of a unique mutation in the Janus kinase-2 gene (JAK2) in polycythemia vera by several independent groups in 2005 quickly spurred the development of the Janus kinase inhibitors.
Pavithran Keechilat +1 more
doaj +2 more sources
Ab initio modeling and experimental assessment of Janus Kinase 2 (JAK2) kinase-pseudokinase complex structure. [PDF]
PLoS Computational Biology, 2013 The Janus Kinase 2 (JAK2) plays essential roles in transmitting signals from multiple cytokine receptors, and constitutive activation of JAK2 results in hematopoietic disorders and oncogenesis.
Xiaobo Wan +4 more
doaj +3 more sources
Assay Development and Inhibitor Screening for Janus Kinase 2 [PDF]
, 2023 Janus kinase 2 (JAK2) is an essential mediator of hematopoietic and growth signaling in cells. It signals as a part of the Janus kinase and signal transducer and activator of transcription (JAK-STAT) pathway, which ultimately regulates gene expression by mediating cytokine signaling from a diverse set of cytokines.
Pölläniemi, Angelika
openaire +3 more sources
Overexpression of Janus kinase 2 protein in extramammary Paget’s disease [PDF]
Japanese Journal of Clinical Oncology, 2021 Abstract Extramammary Paget’s disease is a rare malignant tumor of the skin that occurs primarily in the genitocrural region. Although the prognosis of extramammary Paget’s disease with distant metastasis is poor, an effective therapy has not been established.
Saki, Otsuka-Maeda +13 more
openaire +2 more sources
A JAK of all trades: how global phosphoproteomics reveal the Achilles heel of MPNs
Molecular & Cellular Oncology, 2021 While Janus-kinase (JAK)-inhibitors effectively reduce the inflammatory phenotype of myeloproliferative neoplasms (MPN), they do not affect disease burden or presence of the mutated clone to a major extent. Here, we show how Janus-kinase 2 (JAK2)-mutated
Tina M. Schnoeder +2 more
doaj +1 more source
Journal of Translational Medicine, 2022 Background JAK1 and JAK2 have been implicated in fibrosis and cancer as a fibroblast-related marker; however, their role in liver fibrosis has not been elucidated.
Zhenghui Song +8 more
doaj +1 more source
Journal of the Scientific Society, 2023 Background: Coronavirus disease 2019 (COVID-19), it is an infectious respiratory disease caused by SARS corona virus 2 (SARS CoV-2). There are several reports of using JAK (Janus kinase)-inhibitors in persons with COVID-19 and the use of these decreased ...
Shankar Gharge +3 more
doaj +1 more source
Pharmacology of inhibitors of Janus kinases – Part 2: Pharmacodynamics
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2022 SummaryAs small molecules, the Janus kinase inhibitors have different, dose‐dependent pharmacological binding selectivities, which, however, do not allow reliable statements about the clinical specificity of desired or side effects. It is therefore of particular importance to recognize that the pharmacodynamics of the individual Janus kinase inhibitors
Adina, Eichner, Johannes, Wohlrab
openaire +2 more sources
Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis [PDF]
, 2022 Plaque psoriasis is a common, chronic, systemic, immune-mediated inflammatory disease. The Janus kinase-signal transducer and activator of transcription pathway plays a major role in intracellular cytokine signaling in inflammatory processes involved in ...
Blauvelt, Andrew +2 more
core +1 more source